Becton Dickinson (BDX) and ChemoGLO announced a strategic collaboration to advance hazardous drug contamination testing in health care setting.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target raised to $210 from $197 at Morgan Stanley
- Becton Dickinson Faces Risks in Biosciences and Diagnostic Merger with Waters
- Becton Dickinson Onclarity HPV Assay, BD Viper receive WHO prequalification
- Starboard takes new stake in Bill Holdings, exits Pfizer position
- Becton Dickinson price target lowered to $202 from $211 at RBC Capital